PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

L.
2
83

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

Volume Contents, Author index
and Subject index to
Volume 22

PERGAMON PRESS OXFORD · NEW YORK

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors

Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 Cedar Street, New Haven, Connecticut 06510, USA

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology

Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 George Street, Glasgow G1 1XW, Scotland

Clinical Pharmacology and Therapeutics

Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, Liverpool L69 3BX, England

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Research Triangle Park, North Carolina*
Jürgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
J. Gy Papp—*Szeged, Hungary*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*Cardiff, Wales*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zürich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each.
Annual Subscription, 1984, U.S. $800.00 including postage and insurance, 2 years, 1984/85, U.S. $1520.00.
Specially Reduced Rates to Individuals: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually. Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, USA, and for the remainder of the world to Pergamon Press Ltd, Headington Hill Hall, Oxford OX3 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1984 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproduction, microform or any other reproduction of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical photocopying recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance of $0.50 per page is paid directly to the Copyright Clearance Center Inc., 21 Congress Street, Salem, MA 01970. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon Office.

The Item-Fee Code for this publication is: 0163-7258/83 $0.00 + 0.50

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

Volume 22, 1983, Numbers 1–3

CONTENTS

Number 1

PAGE

Physiology and pharmacology of developing heart cells: *N. Sperelakis and A. J. Pappano* 1
Pharmacology of the developing digestive system: *W. Klinger* 41
Inotropic agents in the treatment of cardiogenic shock: *J. P. Bourdarias, O. Dubourg, P. Gueret, A. Ferrier and J. Bardet* 53
Altered forms of mammalian nucleoside diphosphate reductase from mutant cell lines: *J. A. Wright* 81
The neuropharmacology of schistosomes: *G. R. Hillman* 103
Neurophysiology of adult male *Schistoma mansoni*: *R. A. Pax, C. S. Bricker, D. P. Thompson, D. R. Semeyn and J. F. Bennett* 117
Vasopressin and oxytocin—their role in neurotransmission: *R. M. Buijs* 127
Biosynthesis and processing of neurohypophysial hormones: *B. T. Pickering, R. W. Swann and C. B. Gonzalez* 143

Number 2

Quantitative cytokinetics: cellular response to cell cycle specific agents: *J. W. Gray* 163
Dihydroxyanthraquinone and related *bis* (substituted) aminoanthraquinones: a novel class of antitumor agents: *F. Traganos* 199
Biochemical, structural and mechanical defects of the failing myocardium: *W. H. Newman* 215
Brain and pituitary peptides in thermoregulation: *W. G. Clark and J. M. Lipton* 249
Calcium, drug action and hypertension: *S. Lipe and R. F. W. Moulds* 299

Number 3

Accidental hypothermia: *B. C. Paton* 331
Cellular pharmacokinetics of the phenylalanine mustards: *D. T. Vistica* 379
Delivery of liposome encapsulated drugs to macrophages: *C. R. Alving* 407
Chronobiology and thermoregulation: *A. Reinberg and M. Smolensky* 425

L.
2
83

AUTHOR INDEX

Alving, C. R. 407

Bardet, J. 53
Bennett, J. L. 117
Bourdarias, J. P. 53
Bricker, C. S. 117
Buijs, R. M. 127

Clark, W. G. 249

Dubourg, O. 53

Ferrier, A. 53

Gonzalez, C. B. 143
Gray, J. W. 163
Gueret, P. 53

Hillman, G. R. 103

Klinger, W. 41

Lipe, S. 299
Lipton, J. M. 249

Moulds, R. F. W. 299

Newman, W. H. 215

Pappano, A. J. 1
Paton, B. C. 331
Pax, R. A. 117
Pickering, B. T. 143

Reinberg, A. 425

Semeyn, D. R. 117
Smolensky, M. 425
Sperelakis, N. 1
Swann, R. W. 143

Thompson, D. P. 117
Traganos, F. 199

Vistica, D. T. 379

Wright, J. A. 81

SUBJECT INDEX

Acetylcholine
  developing hearts 5
  schistosomes 107–10
Action potential
  chick heart development 8, 9
  maximum rise rate 10
  rise and overshoot development 9–12
  and tetrodotoxin 11, 12
Adenylate cyclase in heart development 28, 29
ADP
  cell lines reducing 93
  reduction and *N*-carbamoyloxyurea 94
Adrenocorticotropic hormone (ACTH)
  body temperature effects 253
  hypothermic role 252
  physiological role 252
  structure 251
  thermoregulatory effects 250
Age
  body temperature circadian changes 440–2
  thermoregulatory changes 335–7
Amino acids, structures of cyclic 400
Aminoanthroquinones
  active derivatives 204–6
  antiproliferative effects 206–10
  antitumor effects 199–212
  free radical formation 202, 203
  intercalation 201
  membrane effects 203, 204
  nuclease induction 202
  pharmacological parameters 211, 212
  radiation combined 210, 211
  structure–activity relationship 199–201
  structures 199
AMP, cyclic; changes in developing heart 13, 14, 28, 29
AMP, dibutyryl; DNA cell distribution 183
Angiotensin II
  structure 251
  thermoregulatory action 253, 255, 256
Anthracenedione *see also* dihydroxyanthraquinone
  structures 200
Antimony, liver and leishmaniasis treatment 413
Antischistosomal drugs 112
Aphidicolin structure 88
Arabinofuranosyl nucleoside analog structure 88
Ara-C
  cell loss 187, 188
  cell radioactivity 186
  DNA distributions 186
  dose–response curves 180
  KHT cell induced perturbation 191, 192
ATPase, Na–K- in developing heart 5
Automaticity
  developing hearts 7–9
  postdrive hyperpolarization 7
  requirements 7

Benzohydroxamic acid structure 88

Biological rhythms *see also* body temperature, circadian rhythms
  acrophase shifts 434
  body temperature 427–46
  and geographical location 431
  human 425–7
  parameters 427
  synchronizer manipulation 433
  synchronizer phase shift 433–6
Biotransformation reactions, development
  gastrointestinal tract 42–5
    phase I 42, 43
    phase II 43–5
  microflora 45
Body temperature
  biological rhythms 425, 427–46
  circadian rhythms 428–30
    acrophase in obese women and feeding 438–40
    age effects 440–2
    apyretic disease 444, 445
    breast cancer 445
    control mechanisms 443, 444
    drug effects *see* chronopharmacology
    food deprivation 436, 437
    hyperbaric conditions 442, 443
    meal time changes 437–40
    oral cavity tumor 446
    sampling 430
    synchronizer suppression 429, 431
  drugs affecting 446–57
  measurement 425
    hypothermia 341–3
  newborn rhythm 440
  phase shifting 435
  sleep–wake cycle 431–3
Bombesin
  analogs 258, 259
  drug interactions 258, 259
  hypothermic responses 253, 256, 257
    mechanism 257, 258
    site of action 258
  structure 251
Bradykinin 282
  structure 251
Bromodeoxyuridine structure 88

Caerulin 282
  structure 251
Calcium
  altered extracellular concentrations 300, 301
    artery effects 300
    vein effects 300, 301
  ^{45}Ca ion fluxes 303, 304
  chelating agent effects 302
  glyceryl trinitrate and vascular smooth muscle 315–19
  human artery studies 305–7
    and drugs 317–20

human vein studies 307, 308
and drugs 317–20
hydrallazine and vascular smooth muscle 312, 313, 318
hypertensive blood vessel contraction 320–3
and drugs 323
nifedipine and vascular smooth muscle 310–12, 318
nitroprusside and vascular smooth muscle 313–15, 318
sequestration effects on arteries and veins 304, 305
vascular smooth muscle contraction 299–308
and drug effects 308–20
verapamil and vascular smooth muscle 308–10, 317
Calcium antagonists, action potential 12
Cancer therapy
computer optimization 165
kill/cure curves 165
tissue response studies 164
N-carbamoyloxyurea structure 88
Carcinoma, oat cell; neurohypophyseal hormone biosynthesis 155–7
Cardiogenic shock
cardiac tamponade 72, 73
inotropic agent treatment 53–73
myocardial infarction 53–66
postoperative low output syndrome 66–70
pulmonary embolism 70–2
Cardiovascular system
receptor development 28, 29
regulation 25, 26
Carnosine 281
Catecholamines, schistosomes 111, 112
CCK-8 282
structure 251
CDP reductase
cell lines 93
N-carbamoyloxyurea resistant cells 94
hydroxyurea resistant cells 92
Cell cycle phase-specific therapy 178–82
clonogenicity 179
depletion rate measurements 181, 182
phase-specific survival equation 181
post therapy mitosis 182
toxicity 178, 179
phase-specific 179, 180
Cell cycle specific agents *see also* cytokinins
quantitative response 163–94
Cells
CHO 85, 86
ara-C response 180
RC curves 176
cytotoxicity resistance 85
drug resistant, genetic properties 87
drug sensitivity 87
enzyme alterations 88
KHT 169
ara-C and survival 180
pretreatment kinetics 191
Lewis lung 168
Chossat's phenomenon 436, 437
Chronobiology and thermoregulation 425–58 *see also* body temperature
Chronopharmacology and body temperature
ACTH 449–51
concepts 446
corticosteroids 451–4
ethanol 452–5
indomethacin 455–7
lithium 448, 449
placebo effects 446, 447
reserpine 447, 448
Clonogenicity 179
cell kinetics 188, 189
Congestive heart failure
calcium binding 227
induced 221, 224
reversed, length–tension relationships 223
Cryptococcosis, liposome encapsulated drug treatment 417, 418
Cytochrome P-450-dependent oxidation and gastrointestinal development 42, 43
Cytokinetics
cancer therapy 164–6
cell cycle phase-specific therapy 178–82
cell loss 187
RIF tumors 176, 177
continuous labeling 171, 172
DNA distribution analysis 168, 169
fraction of labeled mitoses 172–6
grain count distribution 168, 169
growth fraction 177, 178
parameters 166
quantitative determination 189–92
post-treatment properties 182–9
pre- and mid-therapy state 184
pretreatment properties 166–78
pulse labeling index 167
rate parameter definition 190
serial DNA distributions 185–7
stathmokinetic technique 169–71

Delta sleep inducing peptide (DSIP) 281
structure 251
Digitalis in cardiogenic shock 58–60
Dihydroxyanthraquinone (DHAQ)
activity 204–6
CHO cell staining 205
clearance 211
clinical use 211, 212
dihydrochloride, structure 200
DNA and RNA cell distribution 207
nucleic acid synthesis and EL cells 208, 209
point of action 207, 208
protein synthesis 209, 210
quiescent and cycling cell survival 206
radiation combination 210, 211
structure 200
toxicity 211
and vinblastine effects 208
Dobutamine
cardiogenic shock 61–72
chronic coronary artery disease 63
experimental myocardial ischaemia 62, 63
postoperative low cardiac output 68–70
pulmonary embolism 71, 72
pump failure after myocardial infarction 63–5
resting haemodynamics 61, 62
Dopamine
cardiogenic shock 60, 61
postoperative low cardiac output 67, 68
pulmonary embolism 71
Doxorubicin structure 200

Electrogenic pump in developing heart 6, 7
β-Endorphin

body temperature changes 253, 263–5
drug interactions 265, 266
sites of action 265
mechanism of action 263
structure 251
Enkephalins
analogs 266
body temperature changes 253, 267, 268
fever 270, 271
non-thermal stress 269, 270
thermal stress 269
structures 251
Excitation–contraction coupling defects 224–9
mitochondria 227, 228
myofibrillar ATPase 228, 229
sarcolemmal defects 224–6
sarcoplasmic reticulum 226, 227

Fraction of labeled mitoses (FLM) technique 172–6
cell cycle phase durations 174
RC simulated curves 175
simulated curves 173

Gastrointestinal system
biotransformation reactions 42–5
contractility and drug effects 45–7
developing, pharmacology 41–8
drug absorption development 41, 42
secretory mechanisms and drugs 47, 48
Glucagon 281
cardiogenic shock 54
structure 251
Glucose uptake, developing heart 14
Glucuronidation development in gastrointestinal tract 43, 44
Glutathione development in gastrointestinal tract 44, 45
Gonads, neurohypophyseal hormone biosynthesis 157
Guanazole structure 88

Heart cell development 1–33
autonomic innervation 32, 33
biochemical changes 13, 14
ions 5, 6
metabolic changes 14, 15
pericardium in blastoderm 1, 2
potassium sensitivity 4, 5
receptor changes 28, 29
Heart cell transmitter action 30–2
Heart cell, cultures monolayer 17, 18
Heart failure 215, *see also* myocardium defects
cardiac accelerator stimulation 233
excitation–contraction coupling defects 224–9
Heart, organ cultured 15, 16
cell ultrastructure 16
Histoplasmosis, liposome encapsulated drugs 417, 418
17-Hydroxycorticosteroid, circadian rhythm phase shift 436
5-Hydroxytryptamine, schistosomes 110, 111
Hydroxyurea
cell colony forming ability 85, 86
resistance in cell culture 85, 86
ribonuclease diphosphate reductase inhibition 88

Hypertension in blood vessels and calcium 320–3
altered calcium 321, 322
^{45}Ca fluxes 322, 323
drug effects 323
Hyperthermia definition 444
Hypothalamo–neurohypophyseal system 143, 144
Hypothermia 331–74
acid–base correction 345
age effects 335–7, 369
alcoholics 355
assessment 344
bedroom temperature 361
blood volume correction 345
cardiac drugs 347
cardiorespiratory resuscitation 347, 371
cardiovascular changes 332, 333
circulatory failure 355
definition 444
diagnosis 337–44, 363
diseases inducing 338–41, 363, 364
drugs inducing 340
endocrine changes 334, 335
examination 341–4
exposure duration 338
gastrointestinal tract 333, 334
historical examples 331
kwashiorkor 355
management 344–7
mechanisms 332–7
monitoring 344, 345
myxoedema 355, 356
nervous system changes 333
patient classification 337
respiratory access 356
respiratory system 333
rewarming 348–54 *see also* treatment
access 349
active methods, external and internal 350–4
care 365
method classification 348
non-injurious 348
non-invasive 348
rapid 349
rate 360–2
sheep 366
suitability 349, 350
snorkel 373
state of consciousness 343
temperature taking 341–3
treatment 345–7 *see also* rewarming
clinical results 354–74
glucose response 364
hemodialysis 357
heat exchanges blood 358, 359
mortality 366
mountain rescue 368, 369
outdoor activities 358
pancreas effects 359
peritoneal dialysis 368
prospective study 371
thoracotomy 357, 358
volume expansion 365
urinary bladder temperature 373
Hypothermic agents
TRH analog effects 278
TRH antagonism 272, 273

IMPY structure 88

Inotropic agents *see also* individual drugs
new 65, 66
Isoproterenol
cardiogenic shock 57, 58
postoperative low cardiac output 66, 67
pulmonary embolism 70, 71

Leishmaniasis
liposome use 407
parasitophorous vacuole 410
protozoan localization 409
Liposomes in leishmaniasis 407
cutaneous treatment 416, 417
drug toxicity 417
drug treatment 414–16
parasitophorous vacuole
breakup 412
fusion 410, 411
liposome location 413
Luteinizing hormone-releasing hormone 282
structure 251

Macrophages
cultured liposomes 408
immunomodulator targeting 418–21
liposome-encapsulated drug-delivery 407–22
MAIQ-1 structure 88
α-Melanocyte stimulating hormone (MSH)
structure 251
thermoregulatory effects 253–5
α-Melanocyte stimulating hormone release inhibiting factor (MIF)
hypothermic effects 259, 260
structure 251
Membrane resistance, developing heart cells 3, 4
Metaraminol in cardiogenic shock 55, 56
Methoxamine, cardiogenic shock treatment 53, 54
Mitotic index equation 170
Muramyl dipeptide, melanoma metastases targeting 420
Myocardial blood flow
cardiomyopathies 241, 242
heart failure and hypertrophy 236–42
pressure overload hypertrophy 237–40
renal hypertension 239
vascular resistance and induced hypertrophy 239
volume overload hypertrophy 240, 241
Myocardial failure
contractile state 216, 217
reversibility and hypertrophy 222–4
Myocardial slow channels
acidosis 22
AMP, cyclic effects 20, 21
metabolic factors 21, 22
and phosphorylation 22, 23
positive inotropic agent effects 20
Myocardium defects, failing 215–42
blood flow 236–41
excitation–contraction coupling defects 224–9
pressure overload hypertrophy 219–22
induced 220, 221
sympathetic nervous system 229–36
volume overload hypertrophy 217–19
induced 218, 219
Myofilaments, developing heart 15

Neurohypophyseal hormones *see also* oxytocin, vasopressin
common precursors 144–8
extracerebral biosynthesis 154–7
glycosylation role 150, 151
high molecular weight forms 153, 154
precursor processing 152, 153
Neurotensin
analogs 262, 263
hypothermic responses 253, 261
drug interactions 262
mechanism of action 261, 262
structure 251
Norepinephrine in cardiogenic shock 55, 56
Nucleoside diphosphate reductase
allosteric regulation 83
altered from mutant cells 81–98
drug sensitive activity in mutants 91–6
herpes virus 96, 97
inhibitor structures 88
MI component model 96, 97
model 91
neoplasia 82
structural changes 88–91
structural features 84

Oxytocin 283
amino acid sequences 146
central release 134–6
cysteine incorporation 149
electrophysiological action 136
fiber localization 128–33
electronmicroscopic 133, 134
functions 137, 138
inactivating mechanisms 137
neurotransmission role 127–38
receptor 136
structure 251
Oxytocinergic pathways 129

Pancreas, drug sensitivity of developing 48
Peptides
body temperature 250
structures 251
Phenylalanine mustards 379–402
cell resistance 395–400
dechlorination 399
and glutathione 397–9
clinical pharmacology 395
cytotoxicity
amino acid interactions 387–94
amino acid promotion 389, 390
amino acids reducing 400
cyclic amino acid effects 400–2
evaluation and media 381, 382
in vitro and *in vivo* 391, 392
potentiating agents 394
DNA interaction and cytotoxicity 393, 394
L1210 cells, medium and resistance 382
uptake, drugs affecting 383
membrane transport 383–7
amino acid protection 387
amino acid systems 384–7
cytotoxicity 382
inhibition kinetics 386
leucine effects 385, 386
study 381
structures and isomers 380
tumor interaction with amino acids 392, 393
Phenylephrine, cardiogenic shock 53, 54

Physalaemin 251, 282
Pre-provasopressin, amino acid precursors 148
Pulse labeling index 167
  equation 167
  serial, synchronous cells 184, 185

Receptor
  adrenergic, heart development 28, 29
  muscarinic action 31, 32
  cholinergic muscarinic and heart development 28, 29
    transmitter action 30, 31
Resting potential
  age of development 4
  developing heart 2, 3
Ribonucleotides reduction 81

Salivary glands, drug sensitivity of developing 47, 48
Schistosoma mansoni
  active membrane responses 121, 122
  adult male neurophysiology 117–25
  E_2 compartment 120
  E_3 compartment 120
  electrical compartments 117, 118
  electrical potential recording 122, 123
  intercompartmental coupling 120
  ion, drug effects 118
  microelectrode recordings 117, 118
  muscle responses to electrical stimulation 123, 124
  tegument characteristics 118, 119
Schistosomes
  activity monitoring 105, 106
  drugs affecting 112
  electrophysiological measurements 107
  fluorescent neurotransmitters 106
  model nervous system 107
  neuropharmacology 103–13
    study methods 104, 105
  neurophysiology 117–25
  neurotoxicity measurements 103, 104
  neurotransmitters 107–12
Sodium
  fast channels and tetrodotoxin 17
  heart inward current carrier 11
Sodium channels and heart age 10
Somatostatin
  body temperature changes 253, 271
  structure 251
Stathmokinetic technique 169–71
Stomach, drug sensitivity of developing 48
Substance P 283
  structure 251
Sympathetic nervous system in heart failure 229–36
  altered activity, consequences 232–6
  arterial blood pressure 235
  heart rate 233, 235
  left ventricular contractile force 235
  myocardial norepinephrine 231, 232
  norepinephrine depletion 229–31
    mechanism 232

Targeting *see also* liposomes
  immunomodulators to macrophages 418–21
Tetrodotoxin, heart rate rise 11
Thermoregulation 425–58
  age changes 335, 336
  brain and pituitary peptides 249–87
  derangements 339–41
Thyrotropin releasing hormone (TRH)
  analogs 277, 278
  body temperature changes 253, 271, 272
    body sites 275, 276
    drug interaction 276, 277
    mechanisms of action 272, 274, 275
  hypothermic agent antagonism 272, 273
  structure 251

Vasoactive intestinal peptide (VIP) 283
  structure 251
Vasopressin
  amino acid sequences 146
  biosynthesis 144
  body temperature effects 278, 279
    alcohol 281
    fever 279–81
  cell bodies, suprachiasmatic nucleus 131
  central release 134–6
    veratridine 135
  cysteine incorporation 149
  electrophysiological action 136
  fiber localization 128–33
    electron microscopic 133, 134
    lateral septum 130
  fiber terminations 132, 134
  functions 137, 138
  glycosylated precursors 148–50
  inactivating mechanisms 137
  neurotransmission role 127–38
  precursor 144–8
    processing 152, 153
  receptors 136
  structure 251
Vasopressinergic pathways 129
Vasopressin-neurophysin, lacking in Brattleboro rat 145
Verapamil, action potential in developing heart 12
Virus, herpes ribonuclease reductase 96, 97

Xenopsin 263

PHARMACOLOGY & THERAPEUTICS

Aims and Scope

Pharmacology and Therapeutics presents lucid, critical and authoritative reviews of currently important topics in pharmacology. The articles are normally specially commissioned, although uninvited review papers are occasionally published. When all the manuscripts covering a certain topic have been published, they are reappraised and, if necessary, updated, and then published as a definitive hard bound volume of the *International Encyclopedia of Pharmacology and Therapeutics.*

This policy ensures that each article is published immediately and is not delayed by the later arrival of other manuscripts for the Encyclopedia volume.

Invitation to Authors

Uninvited reviews will be welcomed for editorial consideration and authors should write to the relevant Executive Editor to obtain guidance on how to prepare their manuscripts prior to submitting their reviews.

OL.
22
983

International Encyclopedia of Pharmacology and Therapeutics—Editorial Board

W. C. Bowman—*Strathclyde*
D. C. Bovet—*Rome*
A. M. Breckenridge—*Liverpool*
A. S. V. Burgen—*London*
J. Cheymol—*Paris*
G. B. Koelle—*Philadelphia*
P. Lechat—*Paris*
H. Rašková—*Prague*
A. C. Sartorelli—*New Haven*
V. V. Zakusov—*Moscow*

Some Recent and Forthcoming Encyclopedia Volumes

Section 107 Inhibitors of Mitochondrial Function
Editors: *M. Erecinska and D. F. Wilson*
ISBN 0 08 027380 7 September 1981 348pp

Section 108 Hepatic Cytochrome P-450 Monooxygenase System
Editors: *J. B. Schenkman and D. Kupfer*
ISBN 0 08 027381 5 September 1981 864pp

Section 109 Anti-Hypertensive Drugs
Editor: *A Doyle*
ISBN 0 08 028849 9 February 1982 260pp

Section 110 The Chemotherapy of Psoriasis
Editor: *H. P. Baden*
ISBN 0 08 029823 0 July 1983 310pp

Section 111 Antiviral Chemotherapy, Vol 1
Editor: *D. Shugar*
ISBN 0 08 029821 4 June 1983 504pp

Section 112 Pain and Its Management
Editors: *N. E. Williams and H. Wilson*
ISBN 0 08 029822 2 June 1983 120pp

Section 113 Differentiation Toxicities of Insecticides and Halogenated Aromatics
Editor: *F. Matsumura*
ISBN 0 08 029826 5 November 1983 560pp

Subscribers to the Journal Pharmacology and Therapeutics may purchase individual volumes of the encyclopedia at a 20% reduction on the published price.

Send to your nearest Pergamon Office for details.